{"filings":[{"id":483317,"accession_number":"0001193125-26-228016","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-05-18T13:06:24+00:00","items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Soleno acquisition by Neurocrine Biosciences completed; all shares bought for $53.00 each","event_type":"m_and_a","confidence":"high","bullets":["Tender offer expired May 15 with 88.9% of shares tendered; merger closed May 18, 2026.","Stockholders received $53.00 per share in cash; total offer consideration funded via Neurocrine cash.","All pre-merger directors and officers resigned; new directors and officers from Neurocrine appointed.","Shares to be delisted from Nasdaq and deregistered with SEC; Form 15 to be filed.","Loan agreement with Oxford Finance and 2014 ESPP terminated effective upon merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93113,"accession_number":"0001193125-26-144511","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Soleno withdraws EU marketing application for VIOKAT (PWS hyperphagia)","event_type":"regulatory","confidence":"high","bullets":["Voluntarily withdrew MAA for VIOKAT (diazoxide choline) from EMA for Prader-Willi syndrome hyperphagia.","Decision based on business and strategic considerations; company may re-engage with regulators later.","VIOKAT is marketed in the US as VYKAT XR for adults and children aged 4+ with PWS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93112,"accession_number":"0001193125-26-142911","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Neurocrine to acquire Soleno for $53.00/share in $2.9B all-cash transaction","event_type":"m_and_a","confidence":"high","bullets":["Deal price $53.00 per share; total equity value ~$2.9B; Soleno board recommends shareholders tender.","VYKAT XR generated $190M revenue in 2025, including $92M in Q4 2025; IP expected to extend to mid-2040s.","Conditions include tender of >50% of shares, HSR clearance, no material adverse effect, and customary representations.","Termination fee: $95.25M from Soleno under certain circumstances; $141.5M from Neurocrine if antitrust blocks deal.","Principal stockholders holding ~1.01% of shares have agreed to tender and vote in favor via support agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104471,"accession_number":"0001193125-26-107429","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Soleno amends bylaws with advance notice changes, forum selection, governance updates","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws effective March 16, 2026.","Updated advance notice provisions for stockholder proposals and director nominations.","Amendments reflect recent Delaware law changes and include a forum selection clause.","Certain governance updates and technical/clarifying changes were also made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104470,"accession_number":"0001193125-26-073209","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Soleno Therapeutics appoints Jennifer Fulk as CFO, succeeding retiring James Mackaness","event_type":"leadership","confidence":"high","bullets":["Jennifer Fulk appointed CFO effective March 2, 2026; base salary $525k, target bonus 45%, option for 67,660 shares, RSUs for 39,200 shares.","James Mackaness retiring by end of March 2026, will consult through December 2026 for smooth transition.","Fulk brings 20+ years experience including 15 years at Eli Lilly, most recently CFO/COO at 120Water and CFO at Talkspace.","Fulk will participate in Soleno's Key Executive Change in Control and Severance Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104469,"accession_number":"0001193125-26-071528","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch","event_type":"earnings","confidence":"high","bullets":["FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.","Q4 2025 product revenue $91.7M; full-year revenue $190.4M from VYKAT XR (diazoxide choline).","859 active patients on drug as of Dec 31, 2025; 1,250 patient start forms received since approval.","Cash, cash equivalents and marketable securities $506.1M at year end; $100M share repurchase executed.","First commercial milestone ($7.0M) achieved in Q4 2025; payment due Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":190405000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104468,"accession_number":"0001193125-26-021229","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Soleno Therapeutics approves FY2026 salary hikes, FY2025 bonuses, equity grants, and new severance plan for NEOs","event_type":"other_material","confidence":"high","bullets":["CEO base salary raised to $765k; CFO to $529k; CCO to $515k; SVP Regulatory to $447k.","FY2025 cash bonuses: CEO $487,740; CFO $218,708; CCO $201,588; SVP Reg $161,784.","CEO granted 131,400 stock options and 114,200 RSUs; other NEOs received smaller awards.","New Key Executive Change in Control/Severance Plan offers up to 24 months salary + 150% target bonus + full equity acceleration in change-in-control event.","Outside a change-in-control, CEO gets 18 months salary, 100% target bonus, and 25% equity acceleration; other execs get 9-12 months with no equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104467,"accession_number":"0001193125-26-009886","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno reports preliminary FY2025 VYKAT XR revenue $189M-$191M; profitable","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 net revenue $90M-$92M; full-year net revenue $189M-$191M.","1,250 patient start forms since launch (207 in Q4), ~12.5% of U.S. PWS addressable market.","630 unique prescribers, 136 new in Q4; discontinuation rate ~12% for adverse events.","Achieved profitability and positive cash flow; year-end cash ~$500M after $100M buyback.","Company responded to EMA Day 120 questions; ~60% of total lives covered."],"consensus_eps_estimate":null,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":190405000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120762,"accession_number":"0001193125-25-275674","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Soleno initiates $100M accelerated share repurchase; amends loan facility","event_type":"other_material","confidence":"high","bullets":["Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.","Repurchase expected to complete in Q1 2026; final shares based on VWAP less discount.","Amended Oxford loan facility to permit ASR; $50M committed Term C/D loans removed; remaining $100M uncommitted.","CEO cites Q3 2025 profitability and confidence in VYKAT XR launch as rationale for buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120761,"accession_number":"0001193125-25-264658","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno reports Q3 net income $26M, first profitable quarter; VYKAT XR revenue $66M","event_type":"earnings","confidence":"high","bullets":["Product revenue of $66.0M from VYKAT XR launch (first revenue, vs $0 prior year); net income $26.0M ($0.47 diluted EPS) vs net loss of $76.6M in Q3 2024.","1,043 patient start forms and 764 active patients on VYKAT XR as of Sept 30, 2025; 494 unique prescribers and over 132M lives covered since March approval.","Cash and securities at $556.1M, including $230M gross proceeds from July common stock offering; operating cash flow of $43.5M in Q3.","Sequential product revenue more than doubled from $32.7M in Q2 2025; R&D expense fell to $8.4M from $30.1M, and SG&A to $33.8M from $49.2M.","Appointed Mark W. Hahn to Board of Directors and Audit Committee; contingent consideration liability for Essentialis earnout estimated at $19.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":98675000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120760,"accession_number":"0001193125-25-237854","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Soleno Therapeutics appoints Mark W. Hahn to Board and Audit Committee","event_type":"leadership","confidence":"high","bullets":["Board increased to 7 seats; Hahn appointed as Class II director, term expiring at 2028 annual meeting.","Hahn received 10,046 RSUs vesting over 3 years under Outside Director Compensation Policy.","Hahn most recently was CFO of Verona Pharma through its acquisition by Merck for ~$10B in Oct 2025.","Previously CFO of Dova Pharma (acquired by Sobi for up to $915M) and Cempra (IPO lead).","Hahn brings nearly 30 years of CFO-level experience; certified CPA in Maryland and North Carolina."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137352,"accession_number":"0001193125-25-199882","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Soleno reports death of VYKAT XR patient; company says not drug-related","event_type":"regulatory","confidence":"high","bullets":["A 17-year-old male with lymphedema, thrombophlebitis, and obesity died from pulmonary embolus; FAERS report filed.","Treating physician and Soleno assessed the death as not related to VYKAT XR treatment.","Soleno reaffirms VYKAT XR safety profile and urges use per FDA-approved label.","Company will not comment on future adverse events unless directly linked to VYKAT XR and unexpected per label.","Prader Willi Syndrome patients have reduced life expectancy; mean age of death is 29.5 years per 40-year study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137351,"accession_number":"0001193125-25-182184","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Soleno management to present at Guggenheim/Piper Sandler non-deal roadshow Aug 18-19","event_type":"other_material","confidence":"low","bullets":["Senior management will participate in pre-scheduled investor meetings August 18-19, 2025.","Roadshow is non-deal; hosted by Guggenheim Securities and Piper Sandler.","Corporate presentation attached as Exhibit 99.1, but no specific new data extracted from exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137350,"accession_number":"0001193125-25-174458","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M","event_type":"earnings","confidence":"high","bullets":["Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).","Net loss $(4.7)M or ($0.09) per share vs. $(21.9)M ($0.57) in Q2 2024.","Cash, equivalents and marketable securities $293.8M at June 30; subsequent $230M equity offering in July.","Launch metrics: 646 patient start forms, 295 unique prescribers, >100M lives covered by end of Q2.","MAA for DCCR submitted to EMA; contingent consideration liability for sales milestones estimated at $18.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":32657000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137349,"accession_number":"0001193125-25-157728","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soleno prices $200M public offering of 2.35M shares at $85/share for VYKAT XR commercialization","event_type":"other_material","confidence":"high","bullets":["Priced 2,352,941 shares at $85.00/share; gross proceeds ~$200M before underwriting discounts.","Underwriters have 30-day option to purchase up to an additional 352,941 shares at same price.","Proceeds to fund commercialization of VYKAT XR (diazoxide choline) for Prader-Willi syndrome, approved March 26, 2025.","Also funds EU regulatory/market development, R&D, and general corporate purposes.","Offering expected to close July 11, 2025; joint book-runners: Goldman Sachs, Guggenheim, TD Cowen, Cantor, Oppenheimer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137348,"accession_number":"0001193125-25-157303","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M","event_type":"earnings","confidence":"high","bullets":["Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.","Cash, equivalents & marketable securities at June 30, 2025: ~$293.8 million.","Received 646 patient start forms from ~295 unique prescribers since March 26, 2025 approval.","Debt outstanding under Oxford Financing LLC loan: ~$50.0 million, unchanged.","First revenue quarter for VYKAT XR; financial close and review ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":32657000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154666,"accession_number":"0001193125-25-137047","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Soleno Therapeutics stockholders elect two Class II directors and ratify auditor at 2025 Annual Meeting","event_type":"other","confidence":"high","bullets":["Dr. Anish Bhatnagar re-elected with 42,591,113 votes for (92.3% of voted); William Harris re-elected with 32,331,183 votes for (70.0%).","Appointment of CBIZ CPAs P.C. as independent auditor ratified with 47,253,371 votes for, 8,580 against, 12,015 abstentions.","47,273,966 shares represented (94.7% of outstanding); quorum established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}